To further test this, we utilized the Cancer Therapeutics Response Portal (CTRP) database[23] to analyze the correlation of sensitivity to WEE1 inhibitors with PERK and XBP1s activity, represented by the above described gene signatures of PERK and XBP1s (Table S1, Supporting Information). The gene discussed is WEE1; the disease is cancer.